Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

dendritic cell-CEA peptide vaccine

A cancer vaccine consisting of dendritic cells harvested from a patient with cancer and pulsed or transduced with a peptide fragment of carcinoembryonic antigen (CEA), a tumor-associated antigen expressed by a wide range of cancers. When the altered dendritic cells are returned to the patient, they may stimulate the host immune system to mount a cytotoxic T-lymphocyte immune response against tumor cells expressing CEA.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	CEA peptide-pulsed DC vaccine CEA peptide-pulsed dendritic cell vaccine Dendritic cell-carcinoembryonic antigen peptide vaccine

dendritic cell-CEA peptide vaccine

Search NCI's Drug Dictionary